Overview

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

Status:
NOT_YET_RECRUITING

Trial end date:
2030-06-01

Target enrollment:

Participant gender:

Summary

The investigators plan to conduct an R61/33 hybrid type 2 implementation-effectiveness trial that includes 1) a one-year exploratory R61 phase that will enable the development of the intervention protocol needed for the R33 trial phase including concrete R61 phase milestones; 2) a four-year R33 phase that will include a concurrent implementation evaluation and a randomized control trial.

Phase:

PHASE4

Details

Lead Sponsor:

Duke University

Collaborators:

Friends Research Institute, Inc.
National Institute on Drug Abuse (NIDA)
The Miriam Hospital
University of Arkansas

Treatments:

Buprenorphine
cabotegravir